BMRN vs. ZTS: BioMarin Pharmaceutical vs. Zoetis Stock Comparison

November 11, 2026

How do BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Profile Item	BMRN	ZTS
Name	BioMarin Pharmaceutical Inc.	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	10.85 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	July 26, 1999	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BMRN

ZTS

GSPC

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Total Return (1Y)	8.82%	-30.10%
Total Return (3Y, Annualized)	-12.54%	-20.42%
Total Return (5Y, Annualized)	-7.51%	-16.87%

Risk Profile

Drawdown History

BMRN

ZTS

GSPC

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Volatility (1Y, Annualized)	35.50%	38.23%
Beta (5Y)	0.24	0.66
Max Drawdown (5Y)	-57.64%	-70.45%
Avg. Volume (3M)	2.28M	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

BMRN and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Sharpe Ratio (1Y)	0.13	-0.90
Sortino Ratio (1Y)	0.23	-1.10

Profitability

ROE (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Zoetis (ZTS) reports 57.63%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Max: 109.18%
Q3: 6.23%
BMRN: -0.31%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Zoetis (ZTS) reports 26.41%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
BMRN: -0.52%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Max: 83.12%
BMRN: 26.58%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
ROE (TTM)	-0.31%	57.63%
ROA (TTM)	3.89%	14.87%
Net Margin (TTM)	-0.52%	26.41%
Operating Margin (TTM)	26.58%	38.19%
Gross Margin (TTM)	53.21%	71.65%

Growth

Revenue Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both BioMarin Pharmaceutical (BMRN) at -18.55% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Revenue Growth (YoY)	12.87%	2.28%
Revenue Growth (3Y CAGR)	15.40%	5.42%
EPS Growth (YoY)	-18.55%	10.05%
EPS Growth (3Y CAGR)	33.89%	10.27%

Financial Strength

Current Ratio (MRQ)

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMRN: 2.44
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Max: 1.42
BMRN: 0.67
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Current Ratio (MRQ)	2.44	2.35
Debt / Equity (MRQ)	0.67	2.80
Net Debt / EBITDA	4.04	1.92

Dividends

Dividend Yield (TTM)

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Zoetis (ZTS) trades at 13.50 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BMRN: --

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): BMRN does not report P/E ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMRN: 2.97
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Max: 13.53
Q3: 6.54
Median: 3.25
BMRN: 1.73
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BioMarin Pharmaceutical (BMRN) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioMarin Pharmaceutical (BMRN) and Zoetis (ZTS)
Metric	BMRN	ZTS
P/E Ratio (TTM)	--	13.50
P/S Ratio (TTM)	2.97	3.40
P/B Ratio (MRQ)	1.73	9.80
Free Cash Flow Yield (TTM)	-0.15%	6.36%